News – Complement Therapeutics

Complement Therapeutics Enrols First Patient in Non- interventional i-GAIN Study of People Diagnosed with Geographic Atrophy

admin / February 9, 2023

London England – 09 February 2023 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company, today announced enrolment of...

Press Release

Complement Therapeutics secures Innovate UK EDGE funding to collaborate with the Cell and Gene Therapy Catapult on regulatory strategy for CTx001

admin / November 17, 2022

The Innovate UK EDGE grant funding is awarded to innovative companies looking to benefit from the expertise provided by Catapults...

Press Release

MHRA awards Complement Therapeutics Innovation Passport for CTx001 to accelerate Gene Therapy for Geographic Atrophy

admin / November 1, 2022

MHRA granted Complement Therapeutics an Innovation Passport under the new accelerated Innovative Licensing and Access Pathway (ILAP)ILAP is designed to...

Press Release

Complement Therapeutics Announces the Establishment of its Clinical & Scientific Advisory Board

admin / September 27, 2022

London, England – 27th September 2022 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company, today announced the formation...

Press Release

Complement Therapeutics Ltd announces appointment of Dr Dennis Keefe as Chief Scientific Officer

admin / August 10, 2022

London, England – 10th August 2022 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company focused on the research...

Press Release

Complement Therapeutics Ltd announces appointment of Steve Axon to its Board of Directors

admin / July 18, 2022

Complement Therapeutics Ltd announces appointment of Steve Axon to its Board of Directors London, England – 18th July 2022 -...

Press Release

Complement Therapeutics Ltd raises EUR 5 Million Seed Financing by BGV and Forbion and appoints Dr Rafiq Hasan as CEO

admin / February 23, 2022

Next-generation Complement Therapeutics based on the role of Factor H-related proteins in complement-mediated diseases Company emerges out of stealth mode...